These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 19491650)

  • 21. Reflux after intravitreal injection of bevacizumab.
    Boon CJ; Crama N; Klevering BJ; van Kuijk FJ; Hoyng CB
    Ophthalmology; 2008 Jul; 115(7):1270; author reply 1271. PubMed ID: 18598829
    [No Abstract]   [Full Text] [Related]  

  • 22. Diagnostic and therapeutic challenges.
    Murakami Y; Kusaka S; Oshima Y; Tano Y; Avery RL; Pieramici DJ; Arevalo JF
    Retina; 2008 Oct; 28(9):1357-60. PubMed ID: 19430394
    [No Abstract]   [Full Text] [Related]  

  • 23. Intravitreal bevacizumab for uveitic choroidal neovascularization.
    Doctor PP; Bhat P; Sayed R; Foster CS
    Ocul Immunol Inflamm; 2009; 17(2):118-26. PubMed ID: 19412874
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acute vision loss after intravitreal injection of bevacizumab (avastin) associated with ocular ischemic syndrome.
    Huang ZL; Lin KH; Lee YC; Sheu MM; Tsai RK
    Ophthalmologica; 2010; 224(2):86-9. PubMed ID: 19707032
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases.
    Wakabayashi T; Oshima Y; Sakaguchi H; Ikuno Y; Miki A; Gomi F; Otori Y; Kamei M; Kusaka S; Tano Y
    Ophthalmology; 2008 Sep; 115(9):1571-80, 1580.e1-3. PubMed ID: 18440643
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.
    Arevalo JF; Fromow-Guerra J; Sanchez JG; Maia M; Berrocal MH; Wu L; Saravia MJ; Costa RA;
    Retina; 2008; 28(10):1387-94. PubMed ID: 18827735
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intravitreal bevacizumab (Avastin) for primary treatment of diabetic macular oedema.
    Ozkiriş A
    Eye (Lond); 2009 Mar; 23(3):616-20. PubMed ID: 18437176
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Findings in fluorescein angiography and optical coherence tomography after intravitreal bevacizumab in type 2 idiopathic macular telangiectasia.
    Charbel Issa P; Holz FG; Scholl HP
    Ophthalmology; 2007 Sep; 114(9):1736-42. PubMed ID: 17822979
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intravitreal injection of 2.5 mg versus 1.25 mg bevacizumab (Avastin) for treatment of CNV associated with AMD.
    Modarres M; Naseripour M; Falavarjani KG; Nikeghbali A; Hashemi M; Parvaresh MM
    Retina; 2009 Mar; 29(3):319-24. PubMed ID: 19287288
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metrorrhagia after intravitreal injection of bevacizumab.
    Rodrigues EB; Shiroma H; Meyer CH; Maia M; Farah ME
    Acta Ophthalmol Scand; 2007 Dec; 85(8):915-6. PubMed ID: 17645422
    [No Abstract]   [Full Text] [Related]  

  • 31. Intravitreal bevacizumab in treatment of idiopathic persistent central serous chorioretinopathy: a prospective, controlled clinical study.
    Artunay O; Yuzbasioglu E; Rasier R; Sengul A; Bahcecioglu H
    Curr Eye Res; 2010 Feb; 35(2):91-8. PubMed ID: 20136418
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sequential therapy with intravitreal bevacizumab and photodynamic therapy for idiopathic polypoidal choroidal vasculopathy.
    Pai SA; Shetty R
    Acta Ophthalmol; 2009 Nov; 87(7):806-7. PubMed ID: 18721250
    [No Abstract]   [Full Text] [Related]  

  • 33. [Effectivity and safety of bevacizumab intravitreal injections for exudative age-related macular degeneration treatment--6 months observations].
    Małgorzata F
    Klin Oczna; 2010; 112(7-9):213-6. PubMed ID: 21121123
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Retinal pigment epithelial tears after intravitreal bevacizumab injection for neovascular age-related macular degeneration.
    Chan CK; Meyer CH; Gross JG; Abraham P; Nuthi AS; Kokame GT; Lin SG; Rauser ME; Kaiser PK
    Retina; 2007 Jun; 27(5):541-51. PubMed ID: 17558314
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined intravitreal bevacizumab and argon laser treatment for Coats' disease.
    Cackett P; Wong D; Cheung CM
    Acta Ophthalmol; 2010 Mar; 88(2):e48-9. PubMed ID: 19500078
    [No Abstract]   [Full Text] [Related]  

  • 36. [Intravitreal bevacizumab in the treatment of neovascular glaucoma].
    Ouhadj O; Chergui I; Mendil L; Nouri MT
    J Fr Ophtalmol; 2009 Feb; 32(2):112-6. PubMed ID: 20579473
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Results of 1-year follow-up examinations after intravitreal bevacizumab administration for idiopathic choroidal neovascularization.
    Inoue M; Kadonosono K; Watanabe Y; Sato S; Kobayashi S; Yamane S; Ito R; Arakawa A
    Retina; 2010 May; 30(5):733-8. PubMed ID: 20168271
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Visual improvement in central retinal vein occlusion (CRVO) following intravitreal injections of bevacizumab (Avastin(®) ).
    Algvere PV; Von Wendt G; Gudmundsson J; Seregard S; Kvanta A
    Acta Ophthalmol; 2010 Dec; 88(8):836-41. PubMed ID: 19900206
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intravitreal bevacizumab for idiopathic choroidal neovascularization after previous injection with posterior subtenon triamcinolone.
    Gomi F; Nishida K; Oshima Y; Sakaguchi H; Sawa M; Tsujikawa M; Tano Y
    Am J Ophthalmol; 2007 Mar; 143(3):507-10. PubMed ID: 17317397
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intravitreal bevacizumab for treatment-naïve subfoveal occult choroidal neovascularization in age-related macular degeneration.
    Furino C; Boscia F; Recchimurzo N; Besozzi G; Cardascia N; Sborgia L; Niro A; Sborgia C
    Acta Ophthalmol; 2009 Jun; 87(4):404-7. PubMed ID: 18782335
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.